Search
Glycyrrhiza glabra
go.drugbank.com/drugs/DB14312ApprovedInvestigationalWithdrawnGlycyrrhiza glabra is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: NEW TONIN TROCHE LCategories: Non-Standardized Food Allergenic Extract, Non-Standardized Plant Allergenic ExtractSufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalIt is administered by the intravenous, epidural and sublingual routes. … The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 [L4717].
Synonyms: N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilideCupric oxide
go.drugbank.com/drugs/DB11134ApprovedCupric oxide may be found in over-the-counter vitamin-mineral supplements as a source of [DB09130]. The mean daily dietary intake of copper in adults ranges between 0.9 and 2.2 mg [L2422]. … They may also be produced from electronic wastes. Cupric oxide poses potential health and environmental concern due to toxic and mutagenic particles generating reactive oxygen species [A32656].
Mixtures: Vinate AZ, Folitin-ZLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). … New Zealand and Canada have also followed suit in recalling the drug.
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for … [L9338,L9356] It was also approved by the European Commission on August 17, 2022.[L43997] Traditionally, the triptan class of anti-migraine medications (e.g.
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalIt is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems. … It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease.
Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideClonazepam
go.drugbank.com/drugs/DB01068ApprovedIllicitInvestigationalNow available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. … [FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history